‘Between A Rock And A Hard Place,’ Court Issues Injunction To Halt Praluent Sales
Regeneron and Sanofi have opportunity to appeal or to reach resolution with Amgen after district judge delays imposition of permanent injunction for 30 days in PCSK9 patent case.
You may also be interested in...
Amgen opposes US Federal Circuit's standard for determining adequacy of an invention's written description, which led court to overturn jury verdict that its Repatha patents are valid.
After Shire seeks preliminary injunction to carve-out certain patients from obtaining the hemophilia treatment, Genentech issues open letter saying patients should not be put in the middle of a patent dispute.
Appeals court vacates injunction that Repatha marketer Amgen had won against Sanofi/Regeneron's Praluent, but notes 'a reduction in choice of drugs cannot be the sole reason for a district court to deny an injunction.'